Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 7/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.41 |
| ▸ | PIM1 | P11309 | 2/20 | 0.41 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.41 |
| ▸ | IP6K1 | Q92551 | 3/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
| ▸ | FLT3 | P36888 | 1/20 | 0.38 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.37 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.36 |
| ▸ | IP6K2 | Q9UHH9 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1998529 | 0.92 | SLC2A1 (0.54) | SLC2A1PARP1CHEK1PIM1RPS6KA3 | |
| SCHEMBL1011012 | 0.89 | PARP1 (0.50) | SLC2A1PARP1CHEK1PIM1RPS6KA3 | |
| SCHEMBL8960 | 0.86 | SRC (0.52) | SLC2A1PARP1CHEK1PIM1RPS6KA3 | |
| SCHEMBL297611 | 0.86 | SRC (0.52) | SLC2A1PARP1CHEK1PIM1RPS6KA3 | |
| SCHEMBL1014333 | 0.83 | SRC (0.55) | PARP1CHEK1PIM1RPS6KA3IP6K1 | |
| SCHEMBL1012421 | 0.83 | SRC (0.55) | PARP1CHEK1PIM1RPS6KA3IP6K1 | |
| SCHEMBL4226040 | 0.83 | IP6K1 (0.57) | SLC2A1PARP1IP6K1IP6K3IP6K2 | |
| SCHEMBL4018984 | 0.83 | SLC2A1 (0.46) | SLC2A1PARP1CHEK1PIM1RPS6KA3 | |
| SCHEMBL3725738 | 0.83 | SLC2A1 (0.46) | SLC2A1PARP1CHEK1PIM1RPS6KA3 | |
| SCHEMBL27576840 | 0.82 | SLC2A1 (0.50) | SLC2A1PARP1CHEK1PIM1RPS6KA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021231400-A1 | BIS-ARYL ETHERS CONTAINING N-ACYL AZETIDINE AS EGFR/HER2 INHIBITORS | ACCUTAR BIOTECHNOLOGY, INC. (US) | 2021-11-18 | — | — | WO | disclosed |
| WO-2021231400-A1 | BIS-ARYL ETHERS CONTAINING N-ACYL AZETIDINE AS EGFR/HER2 INHIBITORS | ACCUTAR BIOTECHNOLOGY, INC. (US) | 2021-11-18 | — | — | WO | disclosed |
| US-20170081293-A1 | Functionalized Tyrosine Kinase Inhibitors Modified with Precious Metal Electrophiles and Methods Associated Therewith | WAKE FOREST UNIVERSITY | 2017-03-23 | — | — | US | disclosed |
| EP-1369418-B1 | QUINAZOLINE DERIVATIVES | MITSUBISHI TANABE PHARMA CORP (JP) | 2010-07-28 | — | — | EP | disclosed |
| US-20070265260-A1 | Quinazoline derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-11-15 | — | — | US | disclosed |
| US-7294629-B2 | Quinazoline derivatives | MITSUBISHI PHARMA CORPORATION (JP) | 2007-11-13 | — | — | US | disclosed |
| US-20040116422-A1 | Quinazoline derivatives | MITSUBISHI PHARMA CORPORATION (JP) | 2004-06-17 | — | — | US | disclosed |
| EP-1369418-A1 | QUINAZOLINE DERIVATIVES | Mitsubishi Pharma Corporation (JP) | 2003-12-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170081293-A1 | Functionalized Tyrosine Kinase Inhibitors Modified with Precious Metal Electrophiles and Methods Associated Therewith | ABL1, EGFR, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | SLC2A1 1039/4885PARP1 3817/4885CHEK1 58/4885 |
| US-20070265260-A1 | Quinazoline derivatives | TYK2, ROR1, JAK1 | SLC2A1 3025/4885PARP1 3728/4885CHEK1 446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.